

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Gene expression signature to predict response to CD40-targeted therapy	<p>A gene expression signature that predicts response to CD40-targeted therapy could help guide lymphoma treatment. Gene expression profiling of 7 non-Hodgkin lymphoma (NHL) cell lines identified a 15-gene signature predictive of a therapeutic response to the CD40-stimulating antibody SGN-40. In a retrospective analysis of tissue samples taken from diffuse large B cell lymphoma patients in Phase I and II trials of SGN-40, signature-negative patients showed a median progression-free survival (PFS) of 40 days, whereas signature-positive patients showed a median PFS of 169 days. Next steps could include using the signature to select patients in future anti-CD40 antibody clinical trials.</p> <p>SGN-40 from Seattle Genetics Inc. is in Phase I testing to treat NHL and multiple myeloma (MM).</p> <p>At least five other companies have anti-CD40 antibodies in preclinical to Phase II trials to treat multiple hematological malignancies.</p> <p>SciBX 4(14); doi:10.1038/scibx.2011.414 Published online April 7, 2011</p>	Patent application filed; licensing status undisclosed	<p>Burinton, B. <i>et al. Sci. Transl. Med.</i>; published online March 16, 2011; doi:10.1126/scitranslmed.3001620</p> <p>Contact: David Dornan, Genentech Inc., South San Francisco, Calif. e-mail: dornan.david@gene.com</p>